These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 35683711)

  • 41. Recent advances in anti-multidrug resistance for nano-drug delivery system.
    Wang C; Li F; Zhang T; Yu M; Sun Y
    Drug Deliv; 2022 Dec; 29(1):1684-1697. PubMed ID: 35616278
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates.
    Shaaban MI; Shaker MA; Mady FM
    J Nanobiotechnology; 2017 Apr; 15(1):29. PubMed ID: 28399890
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potential enhancement and targeting strategies of polymeric and lipid-based nanocarriers in dermal drug delivery.
    Kahraman E; Güngör S; Özsoy Y
    Ther Deliv; 2017 Nov; 8(11):967-985. PubMed ID: 29061106
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antimicrobial magnetic nanoparticles based-therapies for controlling infectious diseases.
    Rodrigues GR; López-Abarrategui C; de la Serna Gómez I; Dias SC; Otero-González AJ; Franco OL
    Int J Pharm; 2019 Jan; 555():356-367. PubMed ID: 30453018
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Natural Compounds With Antimicrobial and Antiviral Effect and Nanocarriers Used for Their Transportation.
    Stan D; Enciu AM; Mateescu AL; Ion AC; Brezeanu AC; Stan D; Tanase C
    Front Pharmacol; 2021; 12():723233. PubMed ID: 34552489
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lipid-Based Delivery Systems for Flavonoids and Flavonolignans: Liposomes, Nanoemulsions, and Solid Lipid Nanoparticles.
    Ranjbar S; Emamjomeh A; Sharifi F; Zarepour A; Aghaabbasi K; Dehshahri A; Sepahvand AM; Zarrabi A; Beyzaei H; Zahedi MM; Mohammadinejad R
    Pharmaceutics; 2023 Jul; 15(7):. PubMed ID: 37514130
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives.
    Ali ES; Sharker SM; Islam MT; Khan IN; Shaw S; Rahman MA; Uddin SJ; Shill MC; Rehman S; Das N; Ahmad S; Shilpi JA; Tripathi S; Mishra SK; Mubarak MS
    Semin Cancer Biol; 2021 Feb; 69():52-68. PubMed ID: 32014609
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mycobacterium tuberculosis treatment modalities and recent insights.
    Sukhithasri V; Vinod V; Varma S; Biswas R
    Curr Drug Deliv; 2014; 11(6):744-52. PubMed ID: 24947482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lipid-based Nanocarriers for Cancer and Tumor Treatment.
    Ansari MT; Ramlan TA; Jamaluddin NN; Zamri N; Salfi R; Khan A; Sami F; Majeed S; Hasnain MS
    Curr Pharm Des; 2020; 26(34):4272-4276. PubMed ID: 32693760
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cracking the Challenge of Antimicrobial Drug Resistance with CRISPR/Cas9, Nanotechnology and Other Strategies in ESKAPE Pathogens.
    Zohra T; Numan M; Ikram A; Salman M; Khan T; Din M; Salman M; Farooq A; Amir A; Ali M
    Microorganisms; 2021 Apr; 9(5):. PubMed ID: 33946643
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent Nanocarrier Approaches for Targeted Drug Delivery in Cancer Therapy.
    Bhatia R; Sharma A; Narang RK; Rawal RK
    Curr Mol Pharmacol; 2021; 14(3):350-366. PubMed ID: 32744982
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Solid lipid nanoparticles for hydrophilic drugs.
    Mirchandani Y; Patravale VB; S B
    J Control Release; 2021 Jul; 335():457-464. PubMed ID: 34048841
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Demand for New Antibiotics: Antimicrobial Peptides, Nanoparticles, and Combinatorial Therapies as Future Strategies in Antibacterial Agent Design.
    León-Buitimea A; Garza-Cárdenas CR; Garza-Cervantes JA; Lerma-Escalera JA; Morones-Ramírez JR
    Front Microbiol; 2020; 11():1669. PubMed ID: 32793156
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protein-lipid nanohybrids as emerging platforms for drug and gene delivery: Challenges and outcomes.
    Gaber M; Medhat W; Hany M; Saher N; Fang JY; Elzoghby A
    J Control Release; 2017 May; 254():75-91. PubMed ID: 28365294
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New Generation of Fluconazole: A Review on Existing Researches and Technologies.
    Behtash A; Nafisi S; Maibach HI
    Curr Drug Deliv; 2017; 14(1):2-15. PubMed ID: 27138299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Highlights in nanocarriers for the treatment against cervical cancer.
    Medina-Alarcón KP; Voltan AR; Fonseca-Santos B; Moro IJ; de Oliveira Souza F; Chorilli M; Soares CP; Dos Santos AG; Mendes-Giannini MJS; Fusco-Almeida AM
    Mater Sci Eng C Mater Biol Appl; 2017 Nov; 80():748-759. PubMed ID: 28866224
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nanotechnology: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(19):1-43. PubMed ID: 23074489
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting.
    Gupta U; Jain NK
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):478-90. PubMed ID: 19913579
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alzheimer's Disease and its Related Dementia Types: A Review on Their Management
    Siafaka PI; Mutlu G; Okur NÜ
    Curr Alzheimer Res; 2020; 17(14):1239-1261. PubMed ID: 33602090
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multi-functionalized nanocarriers targeting bacterial reservoirs to overcome challenges of multi drug-resistance.
    Kiani MH; Imran M; Raza A; Shahnaz G
    Daru; 2020 Jun; 28(1):319-332. PubMed ID: 32193748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.